Oral Answers to Questions Debate
Full Debate: Read Full DebateLord Johnson of Marylebone
Main Page: Lord Johnson of Marylebone (Conservative - Life peer)Department Debates - View all Lord Johnson of Marylebone's debates with the Department for Business, Energy and Industrial Strategy
(7 years, 9 months ago)
Commons ChamberAs the Secretary of State has already said, the Government are supporting research and development throughout the UK. We protected the resource budget at the 2015 spending review and committed an extra £2 billion in the most recent autumn statement—the largest increase in science funding since 1979.
A hard Brexit will threaten Scotland’s world-class university sector, and the price of the research development investment that we are discussing was a staggering €8.8 billion from 2007-2013. What representations are this Department making to the Treasury and the Brexit Secretary to protect that vital investment?
Scotland is a powerhouse for academic research, and we want to play to one of this country’s great strengths, so we welcome the agreement to continue to collaborate with our European partners on major science and technology programmes in years to come. Britain will remain at the forefront of collective endeavours to improve and better understand the world in which we live.
The most important investment that we must safeguard is the people who work in science and research. What is the Minister doing to ensure that EU researchers in Scotland are sure of their place as we go through the Brexit process?
The hon. Lady makes an important point. As the Prime Minister made clear in her speech the week before last, we greatly value the contribution that EU nationals make in our institutions. The Government have been exceptionally clear that during the negotiations we want to protect the status of EU nationals already living here. The only circumstances in which that would not be possible are if British citizens’ rights in other EU member states were not protected in return.
We invest £2 billion a year in health life sciences research through our research councils and the National Institute for Health Research. Through funding for the biomedical catalyst, we are helping businesses to bring that research to market. We announced in the new industrial strategy that Sir John Bell will be leading work on a strategy to make the UK the best place in the world to invest in life sciences.
Alongside that welcome support, private investment will be critical to the success of the industry. Will the Minister outline what suggestions he might make in his Budget submission to the Chancellor to stimulate such investment?
My hon. Friend makes an important point. Access to finance is key to a dynamic life sciences sector in the UK. In November, the Prime Minister announced a review of patient capital to identify barriers to access to long-term finance for growing firms, looking at all aspects of the financial system. We look forward to the review’s recommendations ahead of the autumn statement.
The industrial strategy will have a major impact on speeding up Genomics England’s ability to sequence the genome. Will my hon. Friend confirm that he is working with the Department of Health to ensure that the Government’s investment will be spent effectively to encourage greater productivity?
The industrial strategy Green Paper highlights work on a new strategy for life sciences, bringing together the health system, industry and academia and potentially leading to an early sector deal. The accelerated access review sets out a vision of the NHS embracing innovation, and the Government will respond in due course.
This year the Medical Research Council will spend £655 million on world-class research. Our commitment to the future of the UK as a world leader in biomedical research is unwavering. For example, in November, Her Majesty the Queen opened the Francis Crick Institute, and we will continue to invest in this kind of excellence throughout this Parliament.
Autism is the most expensive medical condition in the UK, costing the economy more than £32 billion a year, according to the London School of Economics, yet we spend hardly anything on autism research compared with what we spend on research into cancer, heart disease and stroke, which cost the economy less. What can the Minister do to encourage more spending on autism research, which is so vital to people in this country?
Between 2010-11 and 2014-15, the MRC spent £13.3 million on autism research, and it always welcomes high-quality applications for support on any aspect of human health. Such applications are subject to peer review and are judged in open competition. The Department of Health, through the National Institute for Health Research, also funds research in this area, and the MRC’s centre for neurodevelopmental disorders at King’s College London opened recently, in November.
The right hon. Member for Chesham and Amersham (Mrs Gillan) can always have her question framed and put up on the wall in a suitable part of her home, of her own choosing.